Press Release:

GELSTAT APPOINTS LEO FURCHT, M.D., TO BOARD OF DIRECTORS
Tuesday October 19, 7:04 am ET

ACADEMICIAN, ENTREPRENEUR AND MEDICAL LEADER BRINGS ADDITIONAL BIOTECHNOLOGY AND
PRODUCT DEVELOPMENT EXPERTISE TO BOARD

MINNEAPOLIS, Oct. 19 /PRNewswire-FirstCall/ -- GelStat Corporation (OTC Bulletin
Board: GSAC - News) today announced the appointment of Leo Furcht, M.D. to its
board of directors. Dr. Furcht is a recognized academic and biotechnology
leader, having been instrumental in the success of several pharmaceutical and
medical device companies.

Dr. Furcht is a past founder of ASF, LLC. ASF developed and patented a natural
product for the prescription treatment of mucositis, a serious side effects of
cancer chemotherapy and radiation treatment, which was recently acquired by MGI
Pharma, Inc. in a transaction valued at between $32 to over $60 million. Dr.
Furcht also founded MCL, a stem cell research company that utilizes adult cells
as an effective replacement for embryonic stem cells. MCL has now been acquired
by Athersys, Inc., a development stage biotech company. Dr. Furcht co-founded
South Bay Medical, a medical device company that was acquired by Mentor
Corporation in 2001, and he co-founded Diascreen which was later acquired by
Chronimed. Dr. Furcht was also a venture stage investor in Urologix and United
HealthCare.

"I am very enthusiastic about the many opportunities in front of GelStat," said
Furcht. "I believe my experience in licensing and commercialization of the
prescription use of a natural product will be especially valuable, and I look
forward to working with the GelStat management team to maximize shareholder
value."

"We are very pleased that Dr. Furcht has accepted a position on our board. His
experience in pharmaceutical development and biotechnology will be extremely
valuable as the Company looks to fully exploit additional therapeutic
opportunities in migraine and for other disease states," said Stephen Roberts,
M.D., chairman and chief executive officer of GelStat.

Dr. Furcht is an active faculty member of the University of Minnesota, where he
presently holds the endowed chair as the Allen-Pardee Professor of Cancer
Research, is Head of the Department of Laboratory Medicine and Pathology and is
Medical Director for the Medical Technology Program. He is also the recent past
Director of the Institute of Medical Biotechnology, is the listed inventor of
over 25 issued patents and has published over 130 scientific articles.

With the addition of Dr. Furcht, the GelStat board is now comprised of five
members, three of whom are outsiders.

"This is an important milestone for GelStat," Dr. Roberts said. "It further
prepares us for the listing of our shares on an exchange other than the OTC
Bulletin Board."